Mangalam Drugs And Organics Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mangalam Drugs And Organics Limited has submitted its financial results for the second quarter (Q2) of FY26, covering the period ended September 30, 2025, to the NSE. The filing announcement itself does not contain the detailed revenue, profit, or margin figures, which would be available in the actual results document. No auditor commentary, exceptional items, or restatement details are mentioned in this brief filing notice.
This is a routine regulatory submission confirming that the company has met its listing obligation to file quarterly results on time. Shareholders and investors should look at the detailed results document to evaluate revenue growth, profitability, and margin trends before drawing any conclusions about the stock's direction.